BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/5/2018 6:53:13 PM | Browse: 473 | Download: 461
Category |
Oncology |
Manuscript Type |
Retrospective Study |
Article Title |
Prognostic significance of perioperative tumor marker levels in stage Ⅱ/Ⅲ gastric cancer
|
Manuscript Source |
Invited Manuscript |
All Author List |
Yasuhito Suenaga, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Chie Tanaka, Daisuke Kobayashi, Michitaka Fujiwara, Kenta Murotani and Yasuhiro Kodera |
Funding Agency and Grant Number |
|
Corresponding Author |
Mitsuro Kanda, MD, PhD, Research Fellow, Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. m-kanda@med.nagoya-u.ac.jp |
Key Words |
Gastric cancer; Carcinoembryonic antigen; Carbohydrate antigen 19-9; Perioperative levels; Prognosis |
Core Tip |
Although the outcomes of patients with advanced gastric cancer have gradually improved with the development of adjuvant therapies, a large number of patients experience disease recurrence after curative gastrectomy. To optimize the management of each individual patient, accurate markers to predict prognosis are needed. In this multicenter dataset analysis, we found that evaluation of the serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels both before and after surgery provides more precise risk stratification of patients with stage II/III gastric cancer. Patients with high postoperative CEA and CA19-9 levels are at high risk of disease recurrence, and intensive postoperative management to detect hematogenous recurrences should be considered. |
Citation |
Suenaga Y, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Tanaka C, Kobayashi D, Fujiwara M, Murotani K, Kodera Y. Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. World J Gastrointest Oncol 2019; 11(1): 17-27 |
|
Received |
|
2018-08-16 02:31 |
|
Peer-Review Started |
|
2018-08-17 09:23 |
|
To Make the First Decision |
|
2018-10-08 07:30 |
|
Return for Revision |
|
2018-10-10 00:59 |
|
Revised |
|
2018-11-20 03:17 |
|
Second Decision |
|
2018-11-30 08:32 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2018-12-05 18:53 |
|
Articles in Press |
|
2018-12-05 18:53 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-01-14 08:39 |
ISSN |
1948-5204 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345